Page 2 - கணையம் புற்றுநோய் நடவடிக்கை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

University of Liverpool signs option agreement with BARD1 for type 3C diabetes test The University of Liverpool has signed a two year option agreement with the Australian diagnostics company, BARD1 Life Sciences Ltd, for a type 3c diabetes (T3cDM) blood test. The test uses patented technology developed by researchers in the University of Liverpool s Institute of Systems, Molecular and Integrative Biology. There are around 22.9 million new cases of new-onset diabetes diagnosed around the globe. T3cDM diabetes occurs in around 10 per cent of all new-onset diabetes cases. Currently, no test exists to identify T3cDM and it is most often misdiagnosed as type 2 diabetes (T2DM) and/or inappropriately managed. Approximately 10 in 100 people with T3cDM have underlying pancreatic cancer, with diabetes acting as an early warning sign for the presence of cancer.

United kingdomEithne costelloEmily hendersonCancer researchLife sciences ltdUniversity of liverpool institute systemsEarly detection initiative unitedCancer research united kingdomUniversity of liverpoolSciences ltdMolecular oncologyUnited kingdom early detection initiativeScientific officer dr peter frenchPancreatic cancer actionPancreatic cancer united kingdomNorth west cancer research